JP2023533871A5 - - Google Patents
Info
- Publication number
- JP2023533871A5 JP2023533871A5 JP2023503113A JP2023503113A JP2023533871A5 JP 2023533871 A5 JP2023533871 A5 JP 2023533871A5 JP 2023503113 A JP2023503113 A JP 2023503113A JP 2023503113 A JP2023503113 A JP 2023503113A JP 2023533871 A5 JP2023533871 A5 JP 2023533871A5
- Authority
- JP
- Japan
- Prior art keywords
- unit
- fusion polypeptide
- antigen
- expression
- expression vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20185743.0 | 2020-07-14 | ||
| EP20185743 | 2020-07-14 | ||
| EP20207526 | 2020-11-13 | ||
| EP20207526.3 | 2020-11-13 | ||
| EP21171319.3 | 2021-04-29 | ||
| EP21171319 | 2021-04-29 | ||
| PCT/EP2021/069582 WO2022013277A1 (en) | 2020-07-14 | 2021-07-14 | Apc targeting units for immunotherapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023533871A JP2023533871A (ja) | 2023-08-04 |
| JP2023533871A5 true JP2023533871A5 (enExample) | 2024-07-19 |
Family
ID=79555093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023503113A Pending JP2023533871A (ja) | 2020-07-14 | 2021-07-14 | 免疫療法のためのａｐｃ標的化単位 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230355733A1 (enExample) |
| EP (1) | EP4181949A1 (enExample) |
| JP (1) | JP2023533871A (enExample) |
| AU (1) | AU2021307553A1 (enExample) |
| CA (1) | CA3183951A1 (enExample) |
| WO (1) | WO2022013277A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3216720A1 (en) | 2021-05-10 | 2022-11-17 | Agnete Brunsvik Fredriksen | Co-expression of constructs and immunostimulatory compounds |
| US20250304626A1 (en) | 2021-05-26 | 2025-10-02 | Evaxion Biotech A/S | Vaccination targeting intracellular pathogens |
| CN114106207B (zh) * | 2022-01-24 | 2022-04-26 | 诺未科技（北京）有限公司 | Ccl5的用途 |
| WO2024092025A1 (en) | 2022-10-25 | 2024-05-02 | Nykode Therapeutics ASA | Constructs and their use |
| WO2024100196A1 (en) | 2022-11-09 | 2024-05-16 | Nykode Therapeutics ASA | Co-expression of constructs and polypeptides |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005530761A (ja) * | 2002-05-10 | 2005-10-13 | イネックス ファーマシューティカルズ コーポレイション | 癌ワクチン及びその使用方法 |
| AU2013224658A1 (en) * | 2006-07-21 | 2013-09-19 | California Institute Of Technology | Targeted gene delivery for dendritic cell vaccination |
| KR20130087517A (ko) * | 2010-06-25 | 2013-08-06 | 백시바디 에이에스 | 동종이합체 단백질 구조물 |
| KR20140069222A (ko) * | 2011-09-23 | 2014-06-09 | 유니버시티 오브 오슬로 | 교차 제시 수지상 세포를 표적으로 하는 백시바디 |
| KR102883915B1 (ko) | 2015-12-16 | 2025-11-18 | 시애틀 프로젝트 코포레이션 | 신생항원 동정, 제조, 및 용도 |
| KR102833333B1 (ko) * | 2016-01-08 | 2025-07-11 | 니코데 테라퓨틱스 에이에스에이 | 치료적 항암 네오에피토프 백신 |
| US20180161412A1 (en) * | 2016-12-14 | 2018-06-14 | Cyvax, Inc. | Extended protection protein vaccines against infectious agents |
| EP3612965A4 (en) | 2017-04-19 | 2021-01-13 | Gritstone Oncology, Inc. | NEOANTIGEN IDENTIFICATION, MANUFACTURING AND USE |
| WO2018201017A1 (en) * | 2017-04-27 | 2018-11-01 | Washington University | Dendritic cell targeted adenovirus for vaccination |
| WO2019075112A1 (en) | 2017-10-10 | 2019-04-18 | Gritstone Oncology, Inc. | IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS |
| KR20260008173A (ko) | 2017-11-22 | 2026-01-15 | 시애틀 프로젝트 코포레이션 | 신생항원에 대한 접합 에피토프 제시 감소 |
| BR112021012249A2 (pt) * | 2019-01-04 | 2021-09-08 | Sangamo Therapeutics, Inc. | Métodos e composições para o tratamento da doença de fabry |
| US20230147574A1 (en) * | 2020-04-07 | 2023-05-11 | Evaxion Biotech A/S | Neoepitope immunotherapy with APC targeting unit |
-
2021
- 2021-07-14 JP JP2023503113A patent/JP2023533871A/ja active Pending
- 2021-07-14 CA CA3183951A patent/CA3183951A1/en active Pending
- 2021-07-14 US US18/004,889 patent/US20230355733A1/en active Pending
- 2021-07-14 EP EP21742837.4A patent/EP4181949A1/en active Pending
- 2021-07-14 WO PCT/EP2021/069582 patent/WO2022013277A1/en not_active Ceased
- 2021-07-14 AU AU2021307553A patent/AU2021307553A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023521722A5 (enExample) | ||
| JP7578938B2 (ja) | Ｂ７－ｈ３に対するモノクローナル抗体および細胞治療におけるその使用 | |
| JP7190528B2 (ja) | 神経膠芽腫を治療するための細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む新規複合体 | |
| US8097257B2 (en) | MAGE3 polypeptides | |
| CA2687395C (en) | Complement factor h-derived short consensus repeat-antibody constructs | |
| AU2008310313C1 (en) | A method of transfection and compositions therefor | |
| RU2677799C2 (ru) | Модифицированные суперспиральные белки с улучшенными свойствами | |
| JP2022529989A (ja) | フラジェリン融合タンパク質及びその使用 | |
| KR20190057345A (ko) | 암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체 | |
| IL278418B2 (en) | Vaccine composition | |
| HU228382B1 (en) | Vaccine composition | |
| US11352416B2 (en) | Mosaic chimeric viral vaccine particle | |
| JP2023522588A5 (enExample) | ||
| JP2023533871A (ja) | 免疫療法のためのａｐｃ標的化単位 | |
| JP2023521722A (ja) | Ａｐｃ標的化単位を用いたネオエピトープ免疫療法 | |
| JP6873530B2 (ja) | 自己組織化合成タンパク質（Ｓｅｌｆ−Ａｓｓｅｍｂｌｉｎｇ Ｓｙｎｔｈｅｔｉｃ Ｐｒｏｔｅｉｎｓ） | |
| WO2024222926A1 (zh) | 可自组装为纳米颗粒的融合蛋白及其在免疫中的应用 | |
| JP2006505252A (ja) | 抗原およびアジュバントの多量体複合体 | |
| US10507236B2 (en) | Chimeric proteins | |
| JP2023546485A (ja) | Ｐｄ－ｌ１の細胞外ドメインを含むキメラ抗原 | |
| JP2023546298A5 (enExample) | ||
| Gor et al. | Genetic fusion of three tandem copies of murine C3d sequences to diphtheria toxin fragment B elicits a decreased fragment B-specific antibody response | |
| US20100129383A1 (en) | Bifunctional fusion molecules for the delivery of antigens to professional antigen-presenting cells | |
| CN115197303B (zh) | 一种s蛋白的受体结合结构域的突变体及其应用 | |
| JP7513303B2 (ja) | 腫瘍免疫増強剤、その調製方法および適用 |